CNTX / Context Therapeutics Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Context Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissi

, between Context Therapeutics Inc. and

Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of this 9th day of June, 2025 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Karen Chagin, M.D. (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.” Capitalized words not immediately defined shall

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE

Context Therapeutics Inc. and Dr. K

Exhibit 10.1 Context Therapeutics 2001 Market St, Suite 3915, Unit#15 Philadelphia, PA 19103 April 30, 2025 Dr. Karen Smith [***] Dear Dr. Smith: On behalf of Context Therapeutics Inc. (the “Company”), I am very pleased to offer you the position of Interim Chief Medical Officer, reporting to the Chief Executive Officer. The initial terms of employment are as follows: ■Base Pay: You will be paid an

etween Context Therapeutics

Exhibit 10.2 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the “Agreement”), made as of June 1, 2025 (the “Effective Date”), is by and between Context Therapeutics Inc., a Delaware corporation with an office address at 2001 Market Street, Suite 3915, Unit#15, Philadelphia, PA 19103 (“Company”), and Dr. Karen Smith, with an address of [***] (hereinafter “Consultant”). PREAMBLE WHEREAS, Company de

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Context Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the

June 2025 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025

Exhibit 99.1 Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, PA, April 9, 2025 - Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers fo

PRELIMINARY COPY DATED APRIL 4, 2025, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents PRELIMINARY COPY DATED APRIL 4, 2025, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci

As Filed with the Securities and Exchange Commission on March 20, 2025

As Filed with the Securities and Exchange Commission on March 20, 2025 Registration No.

Description of Securities of Context Therapeutics Inc.

Exhibit 4.4 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2024, Context Therapeutics Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share. The fol

First Amendment to the Development and Manufacturing Services Agreement, dated January 9, 2025, between Lonza Sales AG, Lonza AG and Context Therapeutics Inc. (incorporated by reference to Exhibit 10.15 to the Company's

Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CONFIDENTIAL EXECUTION VERSION FIRST AMENDMENT TO DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT This First Amendment to Development and Manufacturing Services Agreement (this “First Amen

(as assigned to the Company on July

Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL MASTER SERVICES AGREEMENT TABLE OF CONTENTS 2. SCOPE OF THE AGREEMENT 11 2.1. Scope of Agreement 11 2.2. Statements of Work 11 2.2.1. Current Statement of Work 11 2.3. Change Orders 12 2.4.

ontext Therapeutics Inc. Insider Tradi

Exhibit 19 CONTEXT THERAPEUTICS INC. INSIDER TRADING POLICY Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Context Therapeutics Inc. (together with its subsidiaries, the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Dir

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis

JOINT FILING AGREEMENT

Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No.

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress

Exhibit 99.1 Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, PA— January 14, 2025—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engage

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase o

Exhibit 99.1 Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, PA— January 13, 2025—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical co

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis

December 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Exhibit 99.1 Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement

December 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Exhibit 99.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

$75,000,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-268266 PROSPECTUS SUPPLEMENT (To Prospectus dated November 16, 2022) $75,000,000 Common Stock We have entered into a Sales Agreement, or the Sales Agreement, with Leerink Partners LLC, or Leerink Partners, relating to the sale of shares of our common stock, $0.001 par value per share, offered by this prospectus supplement. In accordance with th

Sales Agreement, dated as of December 2, 2024, by and between Context Therapeutics Inc. and Leerink Partners LLC

Exhibit 10.1 CONTEXT THERAPEUTICS INC. Shares of Common Stock ($0.001 par value per share) SALES AGREEMENT December 2, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Context Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issu

CNTX / Context Therapeutics Inc. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

CNTX / Context Therapeutics Inc. / Blue Owl Capital Holdings LP - SC 13G Passive Investment

SC 13G 1 ef20038670sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec

CNTX / Context Therapeutics Inc. / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d1153050813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a

Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103

Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 November 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-283037 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX

CNTX / Context Therapeutics Inc. / Hudson Bay Capital Management LP - CNTX 13G/A Passive Investment

SC 13G/A 1 cntx13ga.htm CNTX 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the approp

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Context Therapeutics Inc.

As filed with the Securities and Exchange Commission on November 6, 2024

As filed with the Securities and Exchange Commission on November 6, 2024 Registration No.

Form of Indenture.

Exhibit 4.3 CONTEXT THERAPEUTICS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series. 5 Section 2.2. E

, 2024, by and between the Company and

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10.

September 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflect

September 2024 Corporate Presentation Advancing T Cell Engagers for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to r

Exhibit 99.1 BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commi

endment to the Amended and Restated Certificate of

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Company”), hereby certifies as follows: FIRST: By unanimous written consent, the Board of Directors approved a proposed amendment to the Amended and Restated Certificate

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commi

Amended & Restated Certificate of Incorporation of Context Therapeutics Inc. as amended through September 17, 2024 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on September 17, 2024).

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. (Composite document reflecting amendments through September 17, 2024) ARTICLE I. The name of the Company is Context Therapeutics Inc. ARTICLE II. The purpose of this company is to engage in any lawful act or activity for which companies may be organized under the General Corporation Law of Delaware. ARTICLE

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipe

Exhibit 99.1 Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy PHILADELPHIA, PA— September 4, 2024—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceuti

Agreement under the Context Therapeutics Inc. 2021 Long-Term Incentive Plan

Exhibit 10.6 Context Therapeutics Inc. 2021 Long -Term Performance Incentive Plan Stock Option Agreement 1.A Stock Option (the “Option”) for a total of [•] shares of $0.001 par value per share of Common Stock (the “Stock”) of Context Therapeutics Inc. (the “Company”), is hereby granted to [•] (the “Optionee”), subject to the terms and provisions of the Context Therapeutics Inc. 2021 Long-Term Perf

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE

Employment Agreement, dated August 1, 2024, between Context Therapeutics Inc. and Claudio Alberto Dansky Ullmann, M.D.

Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of this 1st day of August, 2024 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Claudio Alberto Dansky Ullmann, M.D. (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.” Capitalized words not immed

Form of Stock Option Agreement (Inducement Grant) of Context Therapeutics Inc.

Exhibit 10.5 Context Therapeutics Inc. Stock Option Agreement (Inducement Grant) 1.A Stock Option (the “Option”) for a total of [•] shares of $0.001 par value per share of Common Stock (the “Stock”) of Context Therapeutics Inc. (the “Company”), is hereby granted to [•] (the “Optionee”), subject to the terms and provisions of this Stock Option Agreement (this “Agreement”) and the Context Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

PRELIMINARY COPY DATED JULY 12, 2024, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents PRELIMINARY COPY DATED JULY 12, 2024, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Context Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

July 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Compa

a2024july-contextxcorpde July 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Asset Purchase Agreement, dated July 9, 2024, by and between Company and Link (assignment for the benefit of creditors), LLC (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on July 10, 2024).

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10.

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors

Exhibit 99.1 Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, PA— July 10, 2024—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Context Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

CNTX / Context Therapeutics Inc. / GREAT POINT PARTNERS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

64,515,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-279693 PROSPECTUS 64,515,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders” on page 10 of up to 64,515,000 shares of our common stock, including up to 5,482,741 shares of common stock i

Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103

Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 May 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-279693 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rule

As filed with the Securities and Exchange Commission on May 24, 2024.

As filed with the Securities and Exchange Commission on May 24, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 86-3738787 (State or other jurisdiction of incorporation or organization) (IRS Em

CNTX / Context Therapeutics Inc. / Nextech Crossover I GP S.a r.l. - SC 13G Passive Investment

SC 13G 1 tm2415543d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 21077P108 (CUSIP Number) May 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the

iling Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Context Therapeutics Inc.

CNTX / Context Therapeutics Inc. / Avidity Partners Management LP Passive Investment

SC 13G 1 d1104605913-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) May 2, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

CNTX / Context Therapeutics Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH

Registration Rights Agreement, dated May 1, 2024, by and between the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on May 2, 2024).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 1, 2024 (the “Agreement Date”), by and between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursu

May 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Compan

May 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024

Exhibit 99.2 Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, PA— May 2, 2024 - Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advanci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Context Therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission F

Context Therapeutics Announces $100 Million Private Placement Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028

Exhibit 99.1 Context Therapeutics Announces $100 Million Private Placement Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, PA— May 2, 2024 - Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for sol

Securities Purchase Agreement, dated May 1, 2024, by and between the Company and the Purchasers named therein (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on May 2, 2024).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 1, 2024 (the “Agreement Date”), between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to t

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on May 2, 2024).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers Important Regulatory Milestone Supports Next Phase of CTIM-76 Development

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers Important Regulatory Milestone Supports Next Phase of CTIM-76 Development PHILADELPHIA, PA— April 1, 2024 - Context Therapeutics Inc.

Description of Securities of Context Therapeutics Inc.

Exhibit 4.3 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2023, Context Therapeutics Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share. The fol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci

Compensation Recovery Policy

Exhibit 97 CONTEXT THERAPEUTICS INC. COMPENSATION RECOVERY POLICY Effective May 30, 2023 Policy The Board of Directors (the “Board”) of Context Therapeutics Inc. (the “Company”) has adopted this Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), the Securities and Exchange Commission regulations promulgat

Amended and Restated Bylaws of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Company's Annual Report on Form 10

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on March 19, 2024) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures 2 2.5 Notice Of Stockholders’ Meetings 8 2.6 Quorum 8 2.7

As Filed with the Securities and Exchange Commission on March 21, 2024

As Filed with the Securities and Exchange Commission on March 21, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Context Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio

Bylaws of the Company, effec

US.361564558.01361564558.03 - i - AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on October 21, 2021 and effective as of theMarch 19, 2024) closing of the Company’s initial public offering) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting

March 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Comp

March 2024 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis

Amendment No. 2, dated February 29, 2024, to that certain Research Collaboration and License Agreement, dated April 6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on March 6, 2024)

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT THIS AMENDMENT 2 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment”), is entered into as of the 29th day of February, 20

CNTX / Context Therapeutics Inc. / Affinity Asset Advisors, LLC - AMENDMENT TO FORM SC 13G Passive Investment

SC 13G/A 1 contextsc13ga-123123.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt

CNTX / Context Therapeutics Inc. / Lehr Martin A. - SC 13G/A Passive Investment

SC 13G/A 1 cntx-schedule13gamlehr.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat

CNTX / Context Therapeutics Inc. / Opaleye Management Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address, and Telephone Number of Person Authorized to Receive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

November 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the C

November 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differe

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile CTIM-76 IND filing on track for late Q1 2024 Data to be presented at SITC 38th Annual Meeting on November 3rd PHILADELPHIA, PA— October 31, 2023—Context Therapeutics Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE

August 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Com

a2023augcontextxcorppre August 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Context Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Context Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

PRELIMINARY COPY DATED MARCH 27, 2023, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents PRELIMINARY COPY DATED MARCH 27, 2023, SUBJECT TO COMPLETION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Amendment No. 1, dated March 20, 2023, to that certain Research Collaboration and License Agreement, dated April 6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc.

Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL AMENDMENT 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT THIS AMENDMENT 1 TO RESEARCH COLLABORATION AND LICENSE AGREEMENT (“Amendment”), is entered into as of the 20 day of March, 2023 (

As Filed with the Securities and Exchange Commission on March 22, 2023

As Filed with the Securities and Exchange Commission on March 22, 2023 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC.

March 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Comp

a2023marcontextxcorppre March 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to b

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program Cash runway extended into late 2024 CTIM-76 preclinical data to be presented at AACR Annual Meeting 2023 PHILADELPHIA, PA— March 22, 2023—Context Therapeutics Inc.

Description of Securities of Context Therapeutics Inc.

Exhibit 4.3 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2022, Context Therapeutics Inc. (the “Company,” “we,” “our” and “us”) maintained one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our common stock, par value $0.001 per share (the “Co

Termination Agreement of the Clinical Trial Collaboration and Supply Agreement, dated March 21, 2023 between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group

Exhibit 10.24 TERMINATION AGREEMENT OF THE CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This TERMINATION AGREEMENT OF THE CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of 21 March 2023 (the “Termination Effective Date”), is by and between Context Therapeutics Inc., having a place of business at 2001 Market Street, Suite 3915, Unit# 15, Philadelphia, PA 19103 US

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-40654 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci

CNTX / Context Therapeutics Inc. / Context Therapeutics Inc. - SC 13G Passive Investment

SC 13G 1 cntx-schedule13glehr14feb23.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Context Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage ONA-XR continues to be safe and well-tolerated PHILADELPHIA, PA— February 6, 2023—Context Therapeutics Inc.

February 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking stat

a2023febcontextxcorppre February 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Context Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

CNTX / Context Therapeutics Inc. / HIRSCHMAN ORIN Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No.1 Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 21077P108 (CUSIP Number) January 9, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

January 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking state

contextcorppresentationj January 2023 Corporate Presentation Advancing Medicines for Female Cancers and Other Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with addit

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in 2023 ELONA breast cancer trial open and enrolled first patient PHILADELPHIA, PA— Jan.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Context Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissi

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or th

EX-99.1 2 cntxsabcsdatarelease12722.htm EX-99.1 Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing

December 1, 2022 Identification of CTIM-76, a CLDN6 x CD3 bispecific antibody Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects t

a20221201cldn6rdwebinar- December 1, 2022 Identification of CTIM-76, a CLDN6 x CD3 bispecific antibody Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Context Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commis

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host web

EX-99.1 2 a20221129-contexttherapeut.htm EX-99.1 Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors CTIM-76 named as lead candidate to target Claudin 6 positive cancers IND submission expected in Q1 2024 Context to host webinar on Thursday, December 1, 2022, at 11 a.m. ET PHILADELPHIA, PA — November 29, 2022—Context Therap

5,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS 5,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 10 of up to 5,000,000 shares of our common stock. The selling stockholders or their permitted transfer

Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103

CORRESP 1 filename1.htm Context Therapeutics Inc. 2001 Market Street, Suite 3915, Unit #15 Philadelphia, Pennsylvania 19103 November 14, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Context Therapeutics Inc. Registration Statement on Form S-3 File No. 333-268266 Ladies and Gentlemen: Pursuant to Rule 461 of Reg

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 6 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the “Prospectus”), related to the disposition, from time to time, by the selling sto

Amendment No. 3 to Process Development Agreement & Amendment No. 1 to License, Development, Manufacturing & Marketing Agreement, dated November 7, 2022, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on November 9, 2022).

AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AGREEMENT & AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT This AMENDMENT NO. 3 TO PROCESS DEVELOPMENT AGREEMENT (the ?Development Amendment?) and AMENDMENT NO. 1 TO LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT (the ?License Amendment?, and collectively with the Development Amendment, this ?Amendment?) is effective a

2022, between Lonza Sales AG and Context Therapeutics Inc.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL LICENCE AGREEMENT between LONZA SALES AG and CONTEXT THERAPEUTICS INC.

As filed with the Securities and Exchange Commission on November 9, 2022

As filed with the Securities and Exchange Commission on November 9, 2022 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Context Therapeutics Inc.

Form of Indenture.

Exhibit 4.3 CONTEXT THERAPEUTICS INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 3 Section 1.3. Incorporation by Reference of Trust Indenture Act. 4 Section 1.4. Rules of Construction. 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series. 4 Section 2.2. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX

As filed with the Securities and Exchange Commission on November 9, 2022.

POS AM 1 contexttherapeuticsposamno.htm POS AM As filed with the Securities and Exchange Commission on November 9, 2022. Registration No. 333-261599 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 2 to FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in

November 2022 Corporate Presentation Advancing Medicines for Female Cancers Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the

November 2022 Corporate Presentation Advancing Medicines for Female Cancers Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Development and Manufacturing Services Agreement, dated November 7, 2022, between Lonza Sales AG, Lonza AG and Context Therapeutics Inc. (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on November 9, 2022).

EX-10.3 3 lonzacontextdmsa.htm EX-10.3 CONFIDENTIAL CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Development and Manufacturing Services Agreement between Lonza Sales AG and Lonza AG and Context Therapeutics Inc. 1 CONFIDENTIAL THIS DEVELOPMENT AND

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

CNTX / Context Therapeutics Inc. / HIRSCHMAN ORIN Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Context Therapeutics Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 21077P108 (CUSIP Number) January 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024 Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND

Context Therapeutics? Amends Cash Guidance, Extends Runway into Q1 2024 Company to focus resources on advancing ONA-XR ELONA Phase 1b/2 clinical trial and on advancing CLDN6xCD3 bispecific antibody toward IND PHILADELPHIA, PA? September 27, 2022?Context Therapeutics Inc.

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 5 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commi

September 2022 Corporate Presentation Advancing Medicines for Female Cancers Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Compa

September 2022 Corporate Presentation Advancing Medicines for Female Cancers Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Amendment No. 2 to Consulting Agreement, dated June 17, 2022, between OncoStrategy, LLC and Context Therapeutics Inc.

AMENDMENT NO. 2 TO CONSULTING AGREEMENT This AMENDMENT NO. 2 TO CONSULTING AGREEMENT (this ?Amendment?) is entered into as of the 17th day of June 2022, but effective as of the 1st day of June, 2022 (the ?Amendment Effective Date?), and is entered into by and between OncoStrategy LLC, (?Provider?) and Context Therapeutics Inc., a Delaware corporation, having its principal place of business at 2001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT THE

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 4 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto

Clinical Trial Collaboration and Supply Agreement, dated August 1, 2022, by and between Context Therapeutics Inc. and Berlin-Chemie AG - Menarini Group

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this ?Agreement?), made as of 1 August, 2022 (the ?Effective Date?), is by and between Context Therapeutics Inc.

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 1 Date of Report (Date of earliest event reported): August 1, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

Corporate Presentation August 2022 BRINGING CHANGE FOR FEMALE CANCERS Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s cu

Corporate Presentation August 2022 BRINGING CHANGE FOR FEMALE CANCERS Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement.

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resis

EX-99.1 2 contextandmenarinirelease-.htm EX-99.1 Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 PHILADELPHIA, PA and FLO

10,000,000 Shares Common Stock Context Therapeutics Inc.

424B3 1 prosuppfor8-kjune32022a.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the “Prospectus”), related to the disposit

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commission

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated April 12, 2022) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the ?Prospectus?), related to the disposition, from time to time, by the selling sto

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEXT TH

Form of Common Stock Purchase Warrant.

EX 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION

CNTX / Context Therapeutics Inc. / Affinity Asset Advisors, LLC - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) Michael Hirschberg, Esq. Reitler Kailas & Rosenblatt LLP 885 Third Avenue, 20th Floor New York, NY 10022 (Name, Add

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 110 of up to 10,000,000 shares of our common stock. The selling stockholders or their permitted trans

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

As filed with the Securities and Exchange Commission on April 4, 2022.

As filed with the Securities and Exchange Commission on April 4, 2022. Registration No. 333-261599 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 2834 86-3738787 (State or other jurisdic

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 2 (to prospectus dated December 17, 2021) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 17, 2021 (the ?Prospectus?), related to the disposition, from time to time, by the selli

Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc. and Alex Levit (incorporated by reference to Exhibit 10.17 to the Company's Annual Report on Form 10-K (File No. 001-40654), as filed with the SEC on March 23, 2022).

EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into effective as of this 22nd day of October, 2021 (?Effective Date?) by and between Context Therapeutics Inc.

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.75M initial public offering and

Context Therapeutics? Reports Full Year 2021 Operating and Financial Results Investor R&D event on April 13th to highlight new preclinical data to be presented at AACR Annual Meeting Strong cash position following $28.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 CONTEXT THERAPEUTICS INC. (Exact name of registrant as speci

2022, between OncoStrategy, LLC and Context Therapeutics Inc.

AMENDMENT NO. 1 TO CONSULTING AGREEMENT This AMENDMENT NO. 1 TO CONSULTING AGREEMENT (this ?Amendment?) is entered into as of the 21st day of March 2022, but effective as of the 1st day of February, 2022 (the ?Amendment Effective Date?), and is entered into by and between OncoStrategy LLC, (?Provider?) and Context Therapeutics Inc., a Delaware corporation, having its principal place of business at

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissio

ing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) CONTEXT THERAPEUTICS INC.

As Filed with the Securities and Exchange Commission on March 23, 2022

As Filed with the Securities and Exchange Commission on March 23, 2022 Registration No.

CNTX / Context Therapeutics Inc. / Hudson Bay Capital Management LP - CNTX 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Context Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 21077P108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(3) Registration No. 333-261599 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated December 17, 2021) 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 17, 2021 (the ?Prospectus?), related to the disposition, from time to time, by the selli

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commiss

Corporate Presentation January 2022 BRINGING CHANGE FOR FEMALE CANCERS Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s c

Corporate Presentation January 2022 BRINGING CHANGE FOR FEMALE CANCERS Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company?s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company?s actual activities or results to differ significantly from those expressed in any forward-looking statement.

CNTX / Context Therapeutics Inc. / SABBY MANAGEMENT, LLC - SABBY 13G-A CNTX 1.04.22 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Context Therapeutics® Strengthens Research & Development Team Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D

Context Therapeutics? Strengthens Research & Development Team Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2022 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 86-3738787 (State of other jurisdiction of incorporation) (Commissi

MASTER SERVICES AGREEMENT

MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (this ?Agreement?) is entered into and effective as of January 1, 2022 (the ?Effective Date?) by and between Drug and Device Development Solutions LLC, a North Carolina Limited Liability Corporation, having its principal place of business at [***] (?Provider?), and Context Therapeutics Inc.

Statement of Work No. 1 Provider Services

Statement of Work No. 1 Provider Services This SOW (?SOW?), dated as of January 1, 2022 (the ?SOW Effective Date?), is subject to that certain Master Services Agreement, effective as of January 1, 2022 (the ?Agreement?), by and between Drug and Device Development Solutions LLC, a North Carolina Limited Liability Corporation, having its principal place of business at [***] (?Provider?), and Context

10,000,000 Shares Common Stock Context Therapeutics Inc.

Filed Pursuant to Rule 424(b)(4) Registration No. 333-261599 PROSPECTUS 10,000,000 Shares Common Stock Context Therapeutics Inc. This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders? on page 113 of up to 10,000,000 shares of our common stock. The selling stockholders or their permitted trans

December 14, 2021

December 14, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N.

As filed with the Securities and Exchange Commission on December 10, 2021.

As filed with the Securities and Exchange Commission on December 10, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2566423 (State or other jurisdiction of incorporation or organizatio

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss

Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

EX-99.1 2 contextclosingpressrelease.htm EX-99.1 Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement PHILADELPHIA, PA - December 6, 2021 (GLOBE NEWSWIRE) - Context Therapeutics Inc. (Nasdaq: CNTX) ("Context Therapeutics" or the "Company"), a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological can

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss

Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on December 2, 2021).

EX-4.1 2 cntx-20210930x10qexhibit41.htm EX-4.1 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR

Registration Rights Agreement, dated December 1, 2021, by and between Context Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on December 2, 2021).

EX-10.4 4 cntx-20210930x10qexhibit104.htm EX-10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 1, 2021, by and between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agre

Securities Purchase Agreement, dated December 1, 2021, by and between Context Therapeutics Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 001-40654), as filed with the SEC on December 2, 2021).

EX-10.3 3 cntx-20210930x10qexhibit103.htm EX-10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 1, 2021, between Context Therapeutics Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-40654 CONTEX

Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results Entered into $31.25 million Private Placement Agreement Completed Initial Public Offering of Common Stock and Raised $28.75 million in Gross Proceeds Dosed First Patient

Context Therapeutics? Reports Third Quarter 2021 Operating and Financial Results Entered into $31.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss

Employment Agreement, dated November 1, 2021, between Context Therapeutics Inc. and Jennifer Minai-Azary (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on November 1, 2021).

EX-10.1 2 jminaiemploymentagreementc.htm EX-10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of this 1st day of November, 2021 (“Effective Date”) by and between Context Therapeutics Inc. (the “Company”) and Jennifer Minai-Azary (“Executive”). The Company and Executive are each referred to herein as a “Party” or together as the “Parties.” Capit

Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer -- Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO --

EX-99.1 3 contextcfocloannouncement1.htm EX-99.1 Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer - Company Names Jennifer Minai-Azary as CFO and Announces Alex Levit as CLO - PHILADELPHIA, PA—November 1, 2021—Context Therapeutics Inc. (Nasdaq: CNTX), a women’s oncology company developing advanced small molecule and immunotherap

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 001-40654 47-2566423 (State of other jurisdiction of incorporation) (Commiss

Amended & Restated Bylaws of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).

Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on October 21, 2021 and effective as of the closing of the Company?s initial public offering) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance N

Amended & Restated Certificate of Incorporation of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).

EX-3.1 2 d251040dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a company organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is Context Therapeutics Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of Sta

Amended and Restated Employment Agreement, dated October 22, 2021, between Context Therapeutics Inc. and Martin Lehr (incorporated by reference to the Company’s Current Report on Form 8-K (File No. 001-40654), as filed with the SEC on October 22, 2021).

Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (?Agreement?) is made and entered into effective as of this 22nd day of October, 2021 (?Effective Date?) by and between Context Therapeutics, Inc. (the ?Company?) and Martin Lehr (?Executive?). The Company and Executive are each referred to herein as a ?Party? or together as the ?Parties.? Capital

As Filed with the Securities and Exchange Commission on October 20, 2021

As Filed with the Securities and Exchange Commission on October 20, 2021 Registration No.

ThinkEquity The date of this prospectus is October 19, 2021

Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-256572 PROSPECTUS 5,000,000 Shares Common Stock Context Therapeutics Inc. This is the initial public offering of shares of common stock of Context Therapeutics Inc. We currently operate as a Delaware corporation under the name Context Therapeutics Inc. Prior to this offering, there has been no public market for our common stoc

Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated October 15, 2021 Relating to the Preliminary Prospectus dated October 15, 2021 Registration Statement File No. 333-256572 context therapeutics Advancing Med

Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated October 15, 2021 Relating to the Preliminary Prospectus dated October 15, 2021 Registration Statement File No.

As filed with the Securities and Exchange Commission on October 15, 2021.

Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021.

October 15, 2021

October 15, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N.

October 15, 2021

October 15, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 29, 2021 Relating to the Preliminary Prospectus dated September 29, 2021 Registration Statement File No. 333-256572 context therapeutics Advancing

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 29, 2021 Relating to the Preliminary Prospectus dated September 29, 2021 Registration Statement File No.

As filed with the Securities and Exchange Commission on September 29, 2021.

Table of Contents As filed with the Securities and Exchange Commission on September 29, 2021.

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 24, 2021 Relating to the Preliminary Prospectus dated September 24, 2021 Registration Statement File No. 333-256572 context therapeutics Advancing

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated September 24, 2021 Relating to the Preliminary Prospectus dated September 24, 2021 Registration Statement File No.

Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax

Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR September 24, 2021 Ada Sarmento Tim Buchmiller U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context Therapeutics Inc. (the ?Company?) Amendment No. 4

As filed with the Securities and Exchange Commission on September 24, 2021.

Table of Contents As filed with the Securities and Exchange Commission on September 24, 2021.

context t h er ap eu t i c s Appendix 35 Nasdaq: CNTXcontext t h er ap eu t i c s Appendix 35 Nasdaq: CNTX

context t h er ap eu t i c s Appendix 35 Nasdaq: CNTXcontext t h er ap eu t i c s Appendix 35 Nasdaq: CNTX Appendix Abbreviations AR Androgen Receptor ctDNA Circulating tumor DNA ER Estrogen receptor ESR1 Estrogen receptor 1 gene Ful Fulvestrant GR Glucocorticoid Receptor MAPK Mitogen activated protein kinase mBCa Metastatic breast cancer ONA-IR Onapristone immediate release ONA-XR Onapristone ext

License Agreement, dated August 23, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited.

Exhibit 10.5 CONFIDENTIAL TREATMENT REQUESTED – REDACTED COPY LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT This LICENSE, DEVELOPMENT, MANUFACTURING & MARKETING AGREEMENT (this “Agreement”) is entered into as of August 23, 2021 (the “Effective Date”) by and between Context Therapeutics LLC, a Delaware limited liability company having its registered offices at 3675 Market Street, Suite

As filed with the Securities and Exchange Commission on September 10, 2021.

S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 10, 2021.

August 2, 2021

August 2, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

August 2, 2021

August 2, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N.

July 23, 2021

July 23, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N.

As filed with the Securities and Exchange Commission on July 23, 2021.

Table of Contents As filed with the Securities and Exchange Commission on July 23, 2021.

2

Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 23, 2021 Ada Sarmento Joe McCann U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context Therapeutics Inc. (the ?Company?) Registration Statement o

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Context Therapeutics Inc. (Exact name of registrant as specified in its charter) Delaware 47-2566423 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

July 23, 2021

July 23, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 12, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No. 333-256572 context therapeutics Advancing Medicines

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 12, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No.

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 12, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No. 333-256572 context therapeutics Advancing Medicines

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 12, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No.

Form of Underwriting Agreement.

EX-1.1 2 d46596dex11.htm EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT between Context Therapeutics Inc. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters Context Therapeutics Inc. UNDERWRITING AGREEMENT New York, New York [●], 2021 ThinkEquity A Division of Fordham Financial Management, Inc. As Representative of the several Underwriters nam

Certificate of Amendment to the Certificate of Incorporation.

Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify that: 1. The Certificate of Incorporation of the Corporation is hereby amended by inserting the following paragraph immediately follo

As filed with the Securities and Exchange Commission on July 1, 2021.

Table of Contents As filed with the Securities and Exchange Commission on July 1, 2021.

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 1, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No. 333-256572 context therapeutics Advancing Medicines F

Filed pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus dated July 1, 2021 Relating to the Preliminary Prospectus dated July 1, 2021 Registration Statement File No.

2

Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 1, 2021 Ada Sarmento Joe McCann U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context Therapeutics Inc. (the ?Company?) Registration Statement on

Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax

Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR July 1, 2021 FOIA Confidential Treatment Request Under 17 C.F.R. ?200.83 Ada Sarmento Joe McCann U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: Context

Form of Amended & Restated Certificate of Incorporation of Context Therapeutics Inc. (incorporated by reference to Exhibit 3.3 to the Registration Statement on Form S-1, filed with the Securities and Exchange Commission on May 27, 2021) (File no. 333-256572).

EX-3.3 2 d46596dex33.htm EX-3.3 Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CONTEXT THERAPEUTICS INC. Context Therapeutics Inc., a company organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is Context Therapeutics Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of Stat

Form of Amended and Restated Bylaws (incorporated by reference to Exhibit 3.5 to the Registration Statement on Form S-1, filed with the Securities and Exchange Commission on May 27, 2021) (File no. 333-256572).

EX-3.5 3 d46596dex35.htm EX-3.5 Exhibit 3.5 AMENDED AND RESTATED BYLAWS OF CONTEXT THERAPEUTICS INC. (as amended and restated on , 2021 and effective as of the closing of the Company’s initial public offering) TABLE OF CONTENTS ARTICLE I. CORPORATE OFFICES 1 1.1 Registered Office 1 1.2 Other Offices 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 2.1 Place Of Meetings 1 2.2 Annual Meeting 1 2.3 Special M

As filed with the Securities and Exchange Commission on June 16, 2021.

As filed with the Securities and Exchange Commission on June 16, 2021. Registration No. 333-256572 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CONTEXT THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 2834 47-2566423 (State or other jurisdiction of incorpo

Amendment No. 2 to Process Development Agreement, dated June 3, 2021, between Context Therapeutics LLC and Tyligand Bioscience (Shanghai) Limited (incorporated by reference to Exhibit 10.4 to the Company’s Registration Statement on Form S-1/A (File No. 333-256572), as filed with the SEC on June 16, 2021).

EX-10.4 4 d46596dex104.htm EX-10.4 Exhibit 10.4 AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT This AMENDMENT NO. 2 TO PROCESS DEVELOPMENT AGREEMENT (this “Amendment”) is effective as of this 3rd day of June, 2021 (the “Amendment Effective Date”), and is entered into by and between Tyligand Bioscience (Shanghai) Limited, having its registered office at 3728 Jinke Road, Building 1 West Wing, Zhan

Form of Indemnification Agreement between Context Therapeutics Inc. and its officers and directors (incorporated by reference to Exhibit 10.10 to the Company’s Registration Statement on Form S-1/A (File No. 333-256572), as filed with the SEC on June 16, 2021).

Exhibit 10.10 INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is made as of , 2021 by and between Context Therapeutics Inc., a Delaware corporation (the ?Corporation?), in its own name and on behalf of its direct and indirect subsidiaries, and , an individual (?Indemnitee?). This Agreement supersedes and replaces any and all previous agreements between the Corporation a

Bylaws of Context Therapeutics Inc., as currently in effect.

Exhibit 3.3 BYLAWS OF CONTEXT THERAPEUTICS INC. (Effective as of April 14, 2021) ARTICLE I OFFICES, CORPORATE SEAL Section 1.01 Registered Office. The registered office of the corporation in Delaware shall be that set forth in the Certificate of Incorporation or in the most recent amendment of the Certificate of Incorporation or in a certificate filed with the Secretary of State of the State of De

Voting Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors.

Exhibit 4.4 EXECUTION VERSION VOTING AGREEMENT TABLE OF CONTENTS Page 1. Voting Provisions Regarding the Management Committee. 1 1.1 Units Entitled to Vote for Management Committee 1 1.2 Management Committee Composition 1 1.3 Failure to Designate a Management Committee Member 2 1.4 Removal of Management Committee Members 2 1.5 No Liability for Election of Recommended Managers 3 1.6 No ?Bad Actor?

Investors’ Rights Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors.

Exhibit 4.2 EXECUTION VERSION INVESTORS? RIGHTS AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Registration Rights 4 2.1 Demand Registration 4 2.2 Company Registration 5 2.3 Underwriting Requirements 6 2.4 Obligations of the Company 7 2.5 Furnish Information 8 2.6 Expenses of Registration 9 2.7 Delay of Registration 9 2.8 Indemnification 9 2.9 Reports Under Exchange Act 11 2.10 Limitations o

Research Collaboration and License Agreement, dated April 6, 2021, between Context Therapeutics LLC and Integral Molecular, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).

CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.1 RESEARCH COLLABORATION AND LICENSE AGREEMENT FOR CLAUDIN 6 BISPECIFIC ANTIBODIES BY AND BETWEEN CONTEXT THERAPEUTICS, LLC and INTEGRAL MOLECULAR, INC. APRIL 6, 2021 Certain identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed.

Context Therapeutics Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.6 to the Company’s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).

Exhibit 10.6 CONTEXT THERAPEUTICS INC. 2021 LONG-TERM PERFORMANCE INCENTIVE PLAN 1. PURPOSE OF THE PLAN This 2021 Long-Term Performance Incentive Plan (the ?Plan?) is being established to (a) provide incentives and awards to nonemployee directors, consultants and those employees largely responsible for the long-term success of Context Therapeutics Inc. (the ?Company?) and its 50% or more owned sub

Powers of Attorney (included on signature page).

Table of Contents As filed with the Securities and Exchange Commission on May 27, 2021.

Consulting Agreement, dated October 23, 2019, between William Rencher and Context Therapeutics LLC

CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.10 Context Therapeutics, Inc. 3001 Market Street, Suite 140 Philadelphia, PA 19104 Martin Lehr Chief Executive Officer DATE: October 23, 2019 TO: William F. Rencher, RPh., Ph.D. RE: Letter of Engagement This Letter of Engagement (?LOE?) will serve as the basis under which Drug and Device Development Solutions LLC, a North Carolina Limited

Form of Stock Option Agreement under the Context Therapeutics Inc. 2021 Incentive Award Plan (incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).

Exhibit 10.7 Context Therapeutics Inc. 2021 Long -Term Performance Incentive Plan Stock Option Agreement 1. A Stock Option (the ?Option?) for a total of shares of $0.001 par value per share of Common Stock (the ?Stock?) of Context Therapeutics Inc. (the ?Company?), is hereby granted to (the ?Optionee?), subject to the terms and provisions of the Context Therapeutics Inc. 2021 Long-Term Performance

Right of First Refusal and Co-Sale Agreement, dated December 22, 2020, among Context Therapeutics LLC and certain investors.

Exhibit 4.3 EXECUTION VERSION RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT TABLE OF CONTENTS Page 1. Definitions 1 2. Agreement Among the Company and the Investors 3 2.1 Right of First Refusal 3 2.2 Right of Co-Sale 5 2.3 Effect of Failure to Comply 7 3. Exempt Transfers 7 3.1 Exempted Transfers 7 3.2 Exempted Offerings 8 4. Legend 8 5. Lock-Up 9 5.1 Agreement to Lock-Up 9 5.2 Stop Transfer Instru

Form of Stock Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).

Exhibit 4.1 DELAWARE SEAL CONTEXT THERAPEUTICS INC. CORPORATE April 20, 2021 CT FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF Context Therapeutics Inc. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agen

Consulting Agreement, dated May 7, 2021, between OncoStrategy, LLC and Context Therapeutics Inc. (incorporated by reference to Exhibit 10.12 to the Company’s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).

CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.12 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the ?Agreement?), dated as of May 7, 2021 (the ?Effective Date?), is made by and between Context Therapeutics Inc., Delaware corporation (?Company?), and OncoStrategy, LLC, with its registered address at 4203 Greenspire Lane, New Hope, PA 18938 (hereinafter ?you? or ?Consultant??). PREAMB

Form of Director Services Agreement (incorporated by reference to Exhibit 10.13 to the Company’s Registration Statement on Form S-1 (File No. 333-256572), as filed with the SEC on May 27, 2021).

Exhibit 10.13 BOARD OF DIRECTOR SERVICES AGREEMENT This BOARD OF DIRECTOR SERVICES AGREEMENT (the ?Agreement?) is made and entered into effective as of this 5th day of March 2021 (the ?Effective Date?), by and between Context Therapeutics LLC, a Delaware limited liability company, which is expected to be converted to a Delaware corporation pursuant to a statutory conversion and change its name to

Asset Purchase Agreement, dated as of December 15, 2017, between Context Biopharma Inc. and Arno Therapeutics, Inc.

CONFIDENTIAL TREATMENT REQUESTED - REDACTED COPY Exhibit 10.4 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this ?Agreement?), dated as of December 15, 2017 (the ?Agreement Date?), is entered into by and between Context Biopharma Inc., a Delaware corporation (?Buyer?), and ARNO THERAPEUTICS, INC., a Delaware corporation (?Seller?). Buyer and Seller are referred to collectively herein as